Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19161681 | 0.94 | HDAC6 (0.77) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19168853 | 0.92 | HDAC6 (0.65) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19161255 | 0.92 | HDAC6 (0.78) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19161683 | 0.91 | HDAC6 (0.78) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19161146 | 0.90 | HDAC6 (0.75) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL17520669 | 0.90 | HDAC6 (0.75) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19139005 | 0.90 | HDAC6 (0.75) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19139012 | 0.90 | HDAC6 (0.78) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19161145 | 0.90 | HDAC6 (0.78) | HDAC6HDAC1HDAC4HDAC2HDAC10 | |
| SCHEMBL19161147 | 0.89 | HDAC6 (0.82) | HDAC6HDAC1HDAC4HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
| WO-2016020369-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | HDAC6, HDAC5, HDAC4 | HDAC6 1/4885HDAC1 4/4885HDAC4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.